Foghorn Therapeutics Inc. Operating Cash Flow
Foghorn Therapeutics Inc. (FHTX) reported Operating Cash Flow of -$43.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.84M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.27M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$22.27M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$18.86M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$86.10M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$100.41M.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$118.11M, a 161.00% decline from fiscal 2022.
- Foghorn Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was $193.61M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$43.11M 10-Q · filed 2026-08-06 | -$65.38M derived: sum of 3 quarters · filed 2026-08-06 | -$84.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$25.27M 10-Q · filed 2026-05-07 | -$47.54M derived: sum of 2 quarters · filed 2026-05-07 | -$66.40M derived: sum of 3 quarters · filed 2026-05-07 | -$87.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$22.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$41.13M derived: sum of 2 quarters · filed 2026-03-11 | -$62.13M derived: sum of 3 quarters · filed 2026-08-06 | -$86.10M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$18.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$39.86M derived: sum of 2 quarters · filed 2026-08-06 | -$63.83M 10-Q · filed 2025-11-05 | -$88.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$44.97M 10-Q · filed 2026-08-06 | -$69.49M derived: sum of 3 quarters · filed 2026-08-06 | -$90.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$23.97M 10-Q · filed 2026-05-07 | -$48.49M derived: sum of 2 quarters · filed 2026-05-07 | -$69.49M derived: sum of 3 quarters · filed 2026-05-07 | -$95.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$24.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$45.52M derived: sum of 2 quarters · filed 2026-03-11 | -$71.06M derived: sum of 3 quarters · filed 2026-03-11 | -$100.41M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$21.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$46.54M derived: sum of 2 quarters · filed 2025-11-05 | -$75.89M 10-Q · filed 2025-11-05 | -$103.43M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$25.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$54.88M 10-Q · filed 2025-08-05 | -$82.42M derived: sum of 3 quarters · filed 2025-08-05 | -$109.63M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$29.34M 10-Q · filed 2025-05-14 | -$56.89M derived: sum of 2 quarters · filed 2025-05-14 | -$84.10M derived: sum of 3 quarters · filed 2025-05-14 | -$116.27M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$27.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$54.75M derived: sum of 2 quarters · filed 2025-03-06 | -$86.93M derived: sum of 3 quarters · filed 2025-03-06 | -$118.11M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$27.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$59.38M derived: sum of 2 quarters · filed 2024-11-04 | -$90.56M 10-Q · filed 2024-11-04 | -$119.49M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$32.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$63.35M 10-Q · filed 2024-08-08 | -$92.28M derived: sum of 3 quarters · filed 2024-08-08 | -$112.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$31.18M 10-Q · filed 2024-05-06 | -$60.10M derived: sum of 2 quarters · filed 2024-05-06 | -$80.09M derived: sum of 3 quarters · filed 2024-05-06 | -$109.10M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$28.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$48.91M derived: sum of 2 quarters · filed 2024-03-07 | -$77.92M derived: sum of 3 quarters · filed 2024-03-07 | $193.61M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$19.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$49.00M derived: sum of 2 quarters · filed 2023-11-02 | $222.54M 10-Q · filed 2023-11-02 | $234.42M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$29.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $242.52M 10-Q · filed 2023-08-04 | $254.40M derived: sum of 3 quarters · filed 2023-08-04 | $233.90M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $271.53M 10-Q · filed 2023-05-08 | $283.42M derived: sum of 2 quarters · filed 2023-05-08 | $262.91M derived: sum of 3 quarters · filed 2023-05-08 | $244.43M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $11.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$8.62M derived: sum of 2 quarters · filed 2023-03-09 | -$27.10M derived: sum of 3 quarters · filed 2023-03-09 | -$50.25M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$20.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$38.98M derived: sum of 2 quarters · filed 2022-11-08 | -$62.13M 10-Q · filed 2022-11-08 | -$72.79M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$18.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$41.63M 10-Q · filed 2022-08-09 | -$52.28M derived: sum of 3 quarters · filed 2022-08-09 | -$49.56M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$23.15M 10-Q · filed 2022-05-09 | -$33.80M derived: sum of 2 quarters · filed 2022-08-09 | -$31.08M derived: sum of 3 quarters · filed 2022-08-09 | -$43.67M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | -$10.65M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | -$7.93M derived: sum of 2 quarters · filed 2022-08-09 | -$20.52M derived: sum of 3 quarters · filed 2022-08-09 | -$31.29M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $2.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$9.87M derived: sum of 2 quarters · filed 2021-11-09 | -$20.63M 10-Q · filed 2021-11-09 | -$33.81M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$12.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$23.36M 10-Q · filed 2021-08-10 | -$36.54M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$10.76M 10-Q · filed 2021-05-11 | -$23.95M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$46.34M 10-K · filed 2021-03-18 | ||
| 2019-09-30 | -$33.15M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |